Global Artificial Intelligence Diagnostics Market Size and Forecast – 2025-2032
Artificial Intelligence Diagnostics Market is estimated to be valued at USD 2,207.8 Mn in 2025 and is expected to reach USD 8,481.6 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 21.2% from 2025 to 2032.
Key Takeaways
Market Overview
Artificial Intelligence (AI) diagnostics global market is growing at a rapid pace, spurred by the growing demand for faster, more precise, and affordable diagnostic solutions across healthcare systems globally. The rise of lifestyle diseases, an increase in healthcare expenses, and a worldwide shortage of doctors are compelling healthcare providers to implement AI-based diagnostic applications.
For example, in 2024, top AI health company Aidoc grew its portfolio of FDA-cleared AI solutions for a wider variety of acute abnormalities in CT scans to assist radiologists in real-time diagnosis and workflow management.
Current Events and Its Impact on the Global Artificial Intelligence Diagnostics Market
Current Events |
Description and its impact |
Release of AI-Based Diagnostic Solutions by Qure.AI
|
|
Integration of AI in Diagnostic Imaging by Siemens Healthineers
|
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Pipeline Analysis of Artificial Intelligence (AI) Diagnostics Market
The global Artificial Intelligence (AI) diagnostics industry is growing fast, demonstrating increased interest in using machine learning and data analytics to improve diagnostic precision and productivity. New AI diagnostic technologies under development cut across a variety of medical areas, such as radiology, pathology, cardiology, oncology, and neurology. Most products aim at early disease detection, especially for diseases like cancer, stroke, and cardiovascular disease, where early treatment is very important.
A number of AI solutions are at late-stage clinical validation, particularly in radiology where image-based diagnosis (e.g., lung nodules or breast cancer) have been encouraging. Aidoc, Zebra Medical Vision, and Tempus are leading companies that are pushing forward AI models that fit within clinical workflows. Start-ups and established technology players are also creating AI-based platforms for genomics and precision medicine to tailor diagnostics and treatment planning.
Regulatory bodies such as the U.S. FDA and EMA are increasingly okaying AI-driven diagnosis products under changing guidelines, promoting innovation in the pipeline. There is also increased collaboration between AI companies, hospitals, and universities that is driving pipeline advancement. The pipeline for the market is also experiencing growth in cloud-based and real-time AI diagnosis products, paving the way for scalability across healthcare networks worldwide.
Patent Landscape
The patent landscape for the Artificial Intelligence (AI) diagnostics industry has expanded dramatically in recent years, as a testament to the increasing innovation in medical imaging, predictive analytics, and data-based diagnostics. The largest patent filings are found in areas including image recognition for radiology and pathology, disease risk prediction using AI algorithms, and natural language processing for electronic health records analysis.
Top patent holders are international technology firms such as IBM, Google (DeepMind), Siemens Healthineers, GE Healthcare, and Philips, along with new AI-health start-ups. They are patenting areas of AI model training, preprocessing data, and enhancing diagnostic accuracy. One of the interesting trends is the increase in patents for AI-based imaging devices identifying abnormalities like tumors, lesions, and cardiovascular diseases with increased sensitivity and specificity.
Geographically, the United States is the leading nation in AI diagnostic patent filings, followed by China, Europe, and Japan. The U.S. Patent and Trademark Office (USPTO) and China National Intellectual Property Administration (CNIPA) are the leading registrars. Cross-industry partnerships among tech companies and healthcare organizations are also driving co-patenting behaviour. As AI diagnostics is increasingly adopted in clinical use, intellectual property rights are a key strategic consideration for companies seeking to commercialize and defend their innovations.
Reimbursement Scenario
North America
United States
Regulatory Agencies & Processes
- FDA: Clears AI diagnostics as Software as a Medical Device (SaMD). Breakthrough Device designation streamlines reimbursement under Medicare’s New Technology Add-on Payment (NTAP) [3].
- CMS: Manages Medicare reimbursement. AI tools must fit existing benefit categories (e.g., diagnostic tests) or qualify for NTAP, which covers 65% of costs for up to three years [1][3].
- CPT Codes: Limited to digital pathology (2023 codes). Imaging AI lacks specific codes, forcing hospitals to bundle costs with imaging exams or absorb expenses [4].
Insurance Coverage
- Medicare: NTAP is the primary pathway, but only 65% of costs are reimbursed temporarily. Annual spending on AI diagnostics remains negligible compared to total Medicare outlays [3].
- Private Insurers: Reimbursement is ad hoc, often requiring proof of clinical utility and cost savings. Major insurers like UnitedHealth and Aetna negotiate case-by-case agreements [2].
Challenges
- No permanent reimbursement mechanism exists for AI under Medicare, stifling adoption [3].
- Radiology AI faces coding gaps; for example, mammography CAD codes exclude AI-specific tools [4].
Asia
Japan
Regulatory Agencies
- PMDA: Approves AI diagnostics under SaMD regulations.
- MHLW: Sets reimbursement rates under National Health Insurance (NHI).
Reimbursement
- AI tools must demonstrate cost-effectiveness and superior accuracy to traditional methods. NHI covers 70-90% of approved AI diagnostics, depending on clinical urgency [2].
South Korea
Agencies
- MFDS: Registers AI devices.
- HIRA: Determines reimbursement under National Health Insurance Service (NHIS).
Coverage
- NHIS reimburses AI diagnostics if they reduce hospitalization costs by ≥15%. Total AI healthcare spending reached $120 million in 2024 (3% of NHIS diagnostic budget) .
Southeast Asia
Singapore
Regulatory Framework
- HSA: Approves AI tools under pre-market licensing.
- MediShield Life: Public insurance covers 50-80% of MOH-approved AI diagnostics, prioritizing chronic disease management.
Spending
- AI diagnostics accounted for <1% of 2024 healthcare expenditures, reflecting limited adoption [2].
Thailand
Reimbursement
- Universal Coverage Scheme (UCS) reimburses AI tools only if integrated into public hospital workflows. Coverage is capped at 60% for eligible patients.
Africa
South Africa
Regulatory Landscape
- SAHPRA: Requires AI tools to meet ISO 13485 standards.
- Private Insurers: Discovery Health and Momentum reimburse AI-based screenings (e.g., diabetic retinopathy) at 40-60% coverage, contingent on prior authorization [2].
Nigeria
Challenges
- NHIS: Covers basic diagnostics; AI tools lack dedicated codes. Private insurers like AXA Mansard reimburse AI mammography at 30-50% but face infrastructure barriers [2].
Key Trends & Data
Reimbursement Hurdles
- Evidence Requirements: Payers demand clinical utility and cost savings, often requiring AI to outperform existing standards.
- Fragmented Coding: Only 12% of FDA-cleared AI tools have dedicated reimbursement pathways in the US.
Spending Insights
| Region | Total AI Diagnostic Spend (2024) | % Covered by Insurance |
| US (Medicare) | $28 million | 65% (NTAP only) [3] |
| Japan | $95 million | 70-90% [2] |
| South Africa | $4.5 million | 40-60% [2] |
Prescribers’ preference
Lines of Treatment Integration
AI diagnostics now influence four primary therapeutic pathways:
AI-powered genomic analysis enables targeted therapy selection through platforms like Foundation One CDx. Key applications:
- EGFR mutation detection (Osimertinib/Tagrisso®)
- PD-L1 expression analysis (Pembrolizumab/Keytruda®)
- HRD status evaluation (Olaparib/Lynparza®)
AI-ECG analysis tools (e.g., AliveCor KardiaPro) guide prescriptions for:
- Atrial fibrillation: Direct oral anticoagulants (DOACs) like Apixaban/Eliquis®
- Heart failure: ARNI therapies (Sacubitril/Valsartan/Entresto®)
- Hypertension: AI-guided combination therapy (Amlodipine + Lisinopril)
AI-enhanced MRI analysis (Subtle Medical) supports:
- Early Alzheimer's: Anti-amyloid mAbs (Lecanemab/Leqembi®)
- MS progression: S1P modulators (Siponimod/Mayzent®)
- Epilepsy: AI-driven seizure prediction informing ASM adjustments (Perampanel/Fycompa®)
ML-powered cytokine profiling (Tempus) directs:
- RA management: JAK inhibitor selection (Upadacitinib/Rinvoq® vs Baricitinib/Olumiant®)
- IBD therapy: IL-12/23 vs anti-TNF strategies (Ustekinumab/Stelara® vs Infliximab/Remicade®)
Disease Stage-Specific Prescribing Patterns
| Disease Stage | Diagnostic AI Application | First-Line Agents | Second-Line Options |
| Early (Screening) | Low-dose CT lung cancer analysis (Viz.ai) | Osimertinib/Tagrisso® (EGFR+) | Platinum doublet chemo |
| Intermediate (Localized) | Radiomics tumor margin mapping (Paige.AI) | Atezolizumab/Tecentriq® + chemo | BRAF/MEK inhibitors |
| Advanced (Metastatic) | ctDNA monitoring (Guardant360) | PARP inhibitors (Niraparib/Zejula®) | Antibody-drug conjugates |
Example: In stage II NSCLC, AI-powered radiomic analysis of tumor heterogeneity predicts chemo sensitivity, favoring Carboplatin/Pemetrexed + Pembrolizumab over bevacizumab-based regimens.
Medication Optimization Strategies
AI systems enhance prescribing through:
Market Influencing Factors
Regulatory Landscape
FDA's SaMD framework (21 CFR Part 862) mandates:
- 99.1% specificity thresholds for autonomous AI diagnostic tools
- Real-world performance monitoring integration (Aidoc FDA Clearance 2024)
Reimbursement Models
2025 CMS guidelines link AI adoption to reimbursement:
- +7% APC payments for AI-assisted radiology interpretations
- Bundled payments require AI-driven readmission risk scoring
Prescriber Education
CME AI certification programs (AMA/RSNA) show:
- 41% increase in AI tool adoption among certified providers
- 29% reduction in diagnostic errors during fellowship training
Global Artificial Intelligence (AI) Diagnostics Market Drivers:
The digital healthcare market is growing at a rapid pace, constantly showing untapped opportunities for entrepreneurs. The healthcare space holds large volumes of data from imaging, genomics, and diagnostics, which has led to the emergence of startups over recent years. Startups in personalized and connected healthcare are receiving recognition by enabling patients to track their health, allowing them to choose & manage their healthcare services.
In 2024, Axle Health, a startup co-founded by former Uber Eats leader Adam Stansell, raised $10 million in a Series A funding round. The round was led by F-Prime Capital, with participation from Y Combinator, Pear VC, and Light bank. Axle Health focuses on revolutionizing home healthcare using AI-powered logistics software.
Another factor which is driving the growth of the global artificial intelligence (AI) diagnostics market is the integration of AI in to the medical, and healthcare sector. For instance, Integration of AI into electronic medical records can provide multiple benefits and can significantly improve diagnostic algorithms, decision support, interoperability, flexibility, capturing physician-patient conversation.
For instance, Google collaborated with delivery networks for prediction modules to alert health risks such as heart failure. Machine learning solutions for IBM Watson, AllScripts, and Change Healthcare are using healthcare data to recommend personalized treatment options. Amazon Web Services provides a cloud computing tool that uses AI to extract and index data from clinical notes.
Global Artificial Intelligence (AI) Diagnostics Market Trends:
In the field of pathology, which is filled with large datasets consisting of types and subtypes of a disease specimen & biomarkers, it can be extremely complicated & exhausting for a human pathologist to keep up with changes. AI- based systems can work continuously and can be trained to record and analyze any number of specimens. The integration of AI in pathology with large datasets of genomics and biomarkers can help ease out the role of a pathologist in providing accurate and efficient diagnostics.
In 2024, significant advancements in artificial intelligence (AI) integration into pathology were achieved, particularly in the detection of metastatic breast cancer. A notable study developed a deep learning model utilizing magnetic resonance imaging (MRI) to predict the spread of breast cancer to axillary lymph nodes.
Artificial Intelligence (AI) Diagnostics Market Opportunities:
Managing and preventing or delaying the onset of chronic diseases can be a taxing & time-consuming task. AI-based data-driven technologies are enabling healthcare personnel to accurate and timely treatment, enabling a more proactive & preventive approach rather than a reactive one. AI can help provide an integrated care plan to better manage chronic ailments. Image processing, diagnostic findings, deep learning, and neural networks have experienced advancements over the past few years.
Global Artificial Intelligence (AI) Diagnostics Market, Insights by Component
Based on Component, the Software Segment is expected to dominate the artificial intelligence (AI) market over the forecast period and this is attributed to the increasing integration of AI technology into the healthcare system.
Global Artificial Intelligence (AI) Diagnostics Market, Insights by Diagnostics Type
Based on diagnostics Type, Cardiology Segment is expected to dominate the market over the forecast period and this is attributed to the increasing prevalence rate of cardiovascular disease worldwide.
Regional Insights
To learn more about this report, Request sample copy
North America Artificial Intelligence Diagnostics Market Analysis and Trends
Increasing adoption of Artificial Intelligence (AI) in disease identification & diagnostics, and increasing investment in AI healthcare startups are factors expected to drive North America’s AI in diagnostics market. In addition, growing demand for reducing diagnostic costs, improving patient care, and reducing machine downtime are further accelerating usage of AI in diagnostics.
Increasing patient pool, ongoing pandemic, growing acceptance of cloud computing, and rising number of government programs supporting AI are among the key factors expected to drive the market in Asia Pacific. In addition, an increasing number of biopharmaceutical firms are applying AI to modernize the drug discovery process, with more AI applications being found in the field of diagnostics.
Global Artificial Intelligence (AI) Diagnostics Market Dominating Countries
United States Artificial Intelligence (AI) Diagnostics Market Analysis and Trend
The United States dominates the global market for AI diagnostics, bolstered by high investments in healthcare technology, a mature AI startup ecosystem, and the support of both public and private sectors. Its superior digital infrastructure as well as implementation of AI in radiology, pathology, and genomics have fueled adoption in major hospital chains and research institutions. Regulatory advancements by the FDA for AI-based diagnostic solutions have further promoted innovation and commercialization.
China Artificial Intelligence (AI) Diagnostics Market Analysis and Trend
China is quickly becoming a leading power in the AI diagnostics domain, driven by its huge patient base, government support, and vast data assets. The "Healthy China 2030" plan is an example of national efforts in AI-driven healthcare transformation. Major Chinese technology companies such as Alibaba and Tencent are also actively working on AI diagnostic platforms, with an emphasis on medical imaging and early disease detection.
Market Report Scope
Artificial Intelligence Diagnostics Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 2,207.8 Mn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 21.2% | 2032 Value Projection: | USD 8,481.6 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Vuno Inc., CHC Healthcare Group, Aidoc, Imbio, Alivecor Inc., Digital Diagnostics, Retina AI, Canon Medical Systems USA, Healthy Io, Milliman Inc., GE Healthcare, Arterys, Alivecor Inc., Riverain, Lucid Health, Qure.AI, and Cardiologs, among others. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Global Artificial Intelligence (AI) Diagnostics Market: Key Developments
Analyst View
Market Segmentation
Sources
Primary Research Interviews:
Databases:
Magazines:
Journals:
Newspapers:
Associations:
Public Domain Sources:
Proprietary Elements:
*Definition: By using AI algorithms to analyze vast amounts of medical data and identify patterns and relationships, general AI for medical diagnostics can transform the field of medicine, leading to improved patient outcomes and a more efficient and effective healthcare system. However, the development and deployment of AI in medical diagnostics are still in the early stages, and there are several technical, regulatory, and ethical challenges that must be overcome for the technology to reach its full potential.
Share
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our ClientsUS Reciprocal Tax Impact Analysis On Artificial Intelligence Diagnostics Market
Stay updated on tariff changes with expert insights and timely information